KRAS mutations have been seen at the time of primary and acquired resistance to anti-HER2 therapy in other cancer types, including colorectal and gastroesophageal cancer; however, the impact of KRAS mutations co-occurring with potentially targetable alterations in PDAC has not been defined (11, 18–20). The gene discussed is KRAS; the disease is cancer.